BIOMAT Database Logo BIOMAT Database Logo

Polyactin A increases CD4(+) T-cell counts in HIV-infected individuals with insufficient immunologic response to highly active antiretroviral therapy. 2014

Qi-jian Su, and Yi-zhong Li, and Fei-li Liang, and Jian Xiao, and Xin Deng
Center for AIDS Research, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, Guangxi, PR China.

We conducted a study to determine whether an immunomodulator, polyactin A, is able to enhance the immunologic response in patients with insufficient immunologic response to highly active antiretroviral therapy. From 783 patients, 48 were eligible and were randomly assigned to an experimental group receiving polyactin A for 3 months or a control group. CD4(+) T-cell counts in the experimental group increased from 201 ± 31 to 228 ± 38 cells/µl after treatment (p < 0.001). CD4(+) T-cell counts in the control group and CD8(+) T-cell counts and CD4(+)/CD8(+) ratios in both groups did not differ significantly between baseline and month 3. The experimental group had a higher CD4(+) T-cell count than the control group at month 3 (228 ± 38 versus 205 ± 35, p < 0.05). Our work demonstrated that polyactin A can increase CD4(+) T-cell counts in patients with insufficient immunologic response to highly active antiretroviral therapy, but further studies are required to determine its clinical benefits.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D005260 Female Females
D006020 Glycopeptides Proteins which contain carbohydrate groups attached covalently to the polypeptide chain. The protein moiety is the predominant group with the carbohydrate making up only a small percentage of the total weight. Glycopeptide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

Qi-jian Su, and Yi-zhong Li, and Fei-li Liang, and Jian Xiao, and Xin Deng
Polyactin A can increase CD4+T cell counts in HIV-infected individuals with insufficient immunologic response to HAART: is it a reality?
November 2014, International journal of STD & AIDS,
Qi-jian Su, and Yi-zhong Li, and Fei-li Liang, and Jian Xiao, and Xin Deng
T-cell apoptosis in HIV-1-infected individuals receiving highly active antiretroviral therapy.
March 2001, Blood,
Qi-jian Su, and Yi-zhong Li, and Fei-li Liang, and Jian Xiao, and Xin Deng
CD4+ T cell counts in initiation of antiretroviral therapy in HIV infected asymptomatic individuals; controversies and inconsistencies.
December 2015, Immunology letters,
Qi-jian Su, and Yi-zhong Li, and Fei-li Liang, and Jian Xiao, and Xin Deng
Response to "Micronutrient supplementation increases CD4 count in HIV-infected individuals on highly active antiretroviral therapy: a prospective, double-blinded, placebo-controlled trial".
May 2007, Journal of acquired immune deficiency syndromes (1999),
Qi-jian Su, and Yi-zhong Li, and Fei-li Liang, and Jian Xiao, and Xin Deng
Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy.
May 2002, AIDS (London, England),
Qi-jian Su, and Yi-zhong Li, and Fei-li Liang, and Jian Xiao, and Xin Deng
Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
November 2004, The Journal of infectious diseases,
Qi-jian Su, and Yi-zhong Li, and Fei-li Liang, and Jian Xiao, and Xin Deng
The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy.
May 2003, AIDS (London, England),
Qi-jian Su, and Yi-zhong Li, and Fei-li Liang, and Jian Xiao, and Xin Deng
Long-term follow-up of HIV-infected individuals who have significant increases in CD4+ cell counts during antiretroviral therapy.
November 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Qi-jian Su, and Yi-zhong Li, and Fei-li Liang, and Jian Xiao, and Xin Deng
CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study.
March 1998, Lancet (London, England),
Qi-jian Su, and Yi-zhong Li, and Fei-li Liang, and Jian Xiao, and Xin Deng
Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.
June 2004, Journal of acquired immune deficiency syndromes (1999),
Copied contents to your clipboard!